Difference between revisions of "Team:BGU Israel"

Line 73: Line 73:
 
<td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Design" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/6/6b/Bgu_brush-pencil.png" alt=""></a></div></td>
 
<td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Design" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/6/6b/Bgu_brush-pencil.png" alt=""></a></div></td>
  
<td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_IsraelResults"><div align="center"><img src="https://static.igem.org/mediawiki/2015/b/b9/BGU_home_icon_briefcase.png" alt=""></a></div></td>
+
<td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_IsraelResults"><div align="center"><img src="https://static.igem.org/mediawiki/2015/b/b0/Bgu_brightness.png" alt=""></a></div></td>
<!-- https://static.igem.org/mediawiki/2015/b/b0/Bgu_brightness.png -->
+
<!-- https://static.igem.org/mediawiki/2015/b/b9/BGU_home_icon_briefcase.png -->
  
 
<td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Practices" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/8/89/BGU_Rgb.png" alt=""></a></div></td>
 
<td style="border-style: hidden;"><a href="https://2015.igem.org/Team:BGU_Israel/Practices" ><div align="center"><img src="https://static.igem.org/mediawiki/2015/8/89/BGU_Rgb.png" alt=""></a></div></td>

Revision as of 09:23, 16 September 2015

Team:BGU Israel



Achievements
Project description
Design
Results
Practices and Polices

The Boomerang system:

Despite recent treatment advancements, cancer is still a major cause of mortality worldwide. One of the fundamental problems preventing the development of effective therapy is the difficulty to target cancer cells exclusively.
In Boomerang, we're engineering a genetic device based on a simple concept of AND logic gate: the activation of our CRISPR/Cas9-based system is dependent on the existence of two cancer-specific promoters that control the expression of Cas9 and gRNA, and the combination of these two will occur only in cancer cells. CRISPR/Cas9 system allows several applications of Boomerang: 1) disruption of genes essential for cancer survival; and 2) activation of suicide genes, or color proteins for cancer cell detection (e.g., for complete surgical removal).
Our system can be potentially designed according to unique characteristics of a patient's tumor, paving the way to personalized medicine. We hope that our strategy will change the approach to cancer treatments.